22532 Federal Register / Vol. 87, No. 73 / Friday, April 15, 2022 / Notices 

EIS No. 20220053, Final, MARAD, CA, 

Port of Long Beach Pier B On-Dock 

Rail Support Project, Contact: Alan J. 

Finio 202–366–8024. 

Under 49 U.S.C. 304a(b), MARAD has 

issued a single document that consists 

of a final environmental impact 

statement (FEIS) and record of decision 

(ROD). Therefore, the 30-day wait/ 

review period under NEPA does not 

apply to this action. 

Amended Notice 

EIS No. 20220021, Draft, USFS, AK, 

Mendenhall Glacier Visitor Facility 

Improvements, Comment Period 

Ends: 05/09/2022, Contact: Monique 

Nelson 907–209–4090. Revision to FR 

Notice Published 03/04/2022; 

Extending the Comment Period from 

04/18/2022 to 05/09/2022. 

EIS No. 20220035, Draft, NOAA, OR, 

Western Oregon State Forests Habitat 

Conservation Plan, Comment Period 

Ends: 06/01/2022, Contact: Michelle 

McMullin 541–957–3378. Revision to 

FR Notice Published 03/18/2022; 

Extending the Comment Period from 

05/17/2022 to 06/01/2022. 

Dated: April 11, 2022. 

Cindy S. Barger, 

Director, NEPA Compliance Division, Office 

of Federal Activities. 

[FR Doc. 2022–08096 Filed 4–14–22; 8:45 am] 

BILLING CODE 6560–50–P 

FEDERAL RESERVE SYSTEM 

Formations of, Acquisitions by, and 

Mergers of Savings and Loan Holding 

Companies 

The companies listed in this notice 

have applied to the Board for approval, 

pursuant to the Home Owners’ Loan Act 

(12 U.S.C. 1461 et seq.) (HOLA), 

Regulation LL (12 CFR part 238), and 

Regulation MM (12 CFR part 239), and 

all other applicable statutes and 

regulations to become a savings and 

loan holding company and/or to acquire 

the assets or the ownership of, control 

of, or the power to vote shares of a 

savings association. 

The public portions of the 

applications listed below, as well as 

other related filings required by the 

Board, if any, are available for 

immediate inspection at the Federal 

Reserve Bank(s) indicated below and at 

the offices of the Board of Governors. 

This information may also be obtained 

on an expedited basis, upon request, by 

contacting the appropriate Federal 

Reserve Bank and from the Board’s 

Freedom of Information Office at 

https://www.federalreserve.gov/foia/ 

request.htm. Interested persons may 

express their views in writing on 

whether the proposed transaction 

complies with the standards 

enumerated in the HOLA (12 U.S.C. 

1467a(e)). 

Comments regarding each of these 

applications must be received at the 

Reserve Bank indicated or the offices of 

the Board of Governors, Ann E. 

Misback, Secretary of the Board, 20th 

Street and Constitution Avenue NW, 

Washington, DC 20551–0001, not later 

than May 16, 2022. 

A. Federal Reserve Bank of Richmond 

(Brent B. Hassell, Assistant Vice 

President) P.O. Box 27622, Richmond, 

Virginia 23261. Comments can also be 

sent electronically to 

Comments.applications@rich.frb.org: 

1. Piedmont Financial Holding 

Company, Winston-Salem, North 

Carolina; to become a mutual savings 

and loan holding company upon the 

conversion of Piedmont Federal Savings 

Bank, Winston-Salem, North Carolina, 

from federal mutual savings bank to a 

federal stock savings bank. 

Board of Governors of the Federal Reserve 

System, April 11, 2022. 

Michele Taylor Fennell, 

Deputy Associate Secretary of the Board. 

[FR Doc. 2022–08044 Filed 4–14–22; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Agency for Healthcare Research and 

Quality 

Request for Information: AHRQ’s 

Proposed Patient-Centered Outcomes 

Research Trust Fund Strategic 

Framework; Extension of Comment 

Period 

AGENCY: Agency for Healthcare Research 

and Quality, HHS. 

ACTION: Request for information; notice 

of extension of comment period. 

SUMMARY: In the Federal Register of 

February 18, 2022, the Agency for 

Healthcare Research and Quality 

(AHRQ) announced that it was seeking 

input from the public on its proposed 

strategic framework for AHRQ’s PatientCentered Outcomes Research Trust 

Fund investments. This notice extends 

the comment period 35 days from April 

19, 2022 to May 24, 2022. The subject 

matter content remains unchanged from 

the original notice. 

DATES: Comments on this notice must be 

received by May 24, 2022. AHRQ will 

not respond individually to responders 

but will consider all comments 

submitted by the deadline. 

ADDRESSES: Please submit all responses 

via email to: PCORTF@ahrq.hhs.gov. 

FOR FURTHER INFORMATION CONTACT: 

Karin Rhodes, MD, Chief 

Implementation Officer, Email: 

PCORTF@ahrq.hhs.gov, Telephone: 

301–427–1364 or 240–463–0872. 

SUPPLEMENTARY INFORMATION: AHRQ is 

authorized under 42 U.S.C. 299b–37 to 

broadly disseminate patient-centered 

outcomes research (PCOR) findings, 

including incorporation of PCOR 

findings into health information 

technology focused on clinical decision 

support, and to train researchers in the 

methods used to conduct PCOR. PCOR 

compares the impact of two or more 

preventive, diagnostic, treatment, or 

healthcare delivery approaches on 

health outcomes, including those that 

are meaningful to patients. 

AHRQ’s work under 42 U.S.C. 299b– 

37 is funded by the Patient-Centered 

Outcomes Research Trust Fund 

(PCORTF), 26 U.S.C. 9511, which was 

established in 2010 and reauthorized in 

2019. To learn more about the PCORTF, 

please visit: https://www.ahrq.gov/pcor/ 

potential-of-the-pcortf/index.html. 

In response to the reauthorization of 

the PCORTF, AHRQ has developed a 

proposed strategic framework to guide 

future planning and evaluation of 

AHRQ’s PCORTF investments (the 

strategic framework). The strategic 

framework is consistent with AHRQ’s 

broader goal of improving the quality, 

safety, equity, and value of healthcare 

delivery. 

The proposed strategic framework 

identifies five priorities for improving 

healthcare delivery that are aligned with 

AHRQ’s mission and that have the 

potential to improve outcomes that 

patients care about. These priorities are 

interrelated, and all contribute to 

achieving the proposed strategic 

framework’s overall vision of equitable 

whole-person care across the lifespan. 

The proposed strategic framework is 

consistent with AHRQ’s Congressional 

authorization for investments from the 

PCORTF and is aligned with national 

health priorities. 

The AHRQ PCORTF strategic 

framework includes a mission, vision, 

high-level priorities, desired outcomes, 

and cross-cutting strategies for 

advancing the desired outcomes. This 

framework is expected to describe and 

inform the portfolio of AHRQ PCORTF 

investments. AHRQ will use this broad 

framework to guide long-range planning 

and to guide the development of 

projects and investments. 


jspears on DSK121TN23PROD with NOTICES1
Federal Register / Vol. 87, No. 73 / Friday, April 15, 2022 / Notices 22533 

AHRQ PCORTF-funded projects will 

be connected to components and subcomponents of the strategic framework. 

Use of the strategic framework is 

intended to ensure that AHRQ’s 

investments are coherently connected 

and advance the overall vision of 

advancing equitable whole-person care 

across the lifespan. The final strategic 

framework will also provide a basis for 

creating an evaluation framework, 

measuring the success of individual 

projects, and identifying the overall 

impact of AHRQ’s PCORTF 

investments. 

AHRQ is seeking public comment on 

the proposed strategic framework for 

AHRQ’s PCORTF investments. 

BILLING CODE 4160–90–P 

BILLING CODE 4160–90–C 

AHRQ hopes to receive feedback from 

patients, healthcare professionals, 

community groups, employers, health 

services researchers, dissemination and 

implementation scientists, 

communications experts, 

representatives from health systems, 

public and private payers, and other 

stakeholders. 

The input received from this public 

comment period will be used in refining 

and finalizing the strategic framework. 

Based on the final strategic framework, 

AHRQ intends to develop an 

operational plan, which will include 

specific short- and long-term objectives 

and a formative and summative 

evaluation. The overall goal of AHRQ’s 

planning process is to identify 

investments consistent with its PCORTF 

authorization that will have the greatest 

positive impact on health and 

healthcare. 

AHRQ is requesting information from 

the public regarding the following broad 

questions: 

1. AHRQ would like overall reactions 

to the strategic framework; is there any 

aspect of the framework that: 

a. Does not promote the vision of 

advancing equitable whole-person care 

across the lifespan? 

b. Does not address major challenges 

faced by the U.S. healthcare system? 

c. Could be improved (and if so, 

how)? 

2. AHRQ would like input on our 

(non-ranked) high-level priority areas: 

a. Do our proposed high-level 

priorities miss any areas of critical 

importance? 

b. Are any of the high-level priorities 

more important than others? 

3. AHRQ would like input on how to 

target investments within high-priority 

areas. For example, should AHRQ focus 

on: 

a. Specific ages/stages or apply 

AHRQ’s investments equally across the 

lifespan? 

b. Transitions in care? 

4. AHRQ would also appreciate 

suggestions for applying the strategic 

framework. For example: 

a. How can AHRQ improve the 

dissemination of patient-centered 

outcomes research evidence to decisionmakers at the local, State, and Federal 

levels? 

b. What targeted investments could 

AHRQ make to sustain progress towards 

the strategic framework’s desired 

outcomes? 

c. What AHRQ PCORTF investments 

could help improve healthcare provider 

trust, well-being, and retention? 


jspears on DSK121TN23PROD with NOTICES1EN15AP22.038</GPH>
22534 Federal Register / Vol. 87, No. 73 / Friday, April 15, 2022 / Notices 

5. How can AHRQ have the greatest 

impact and success at achieving the 

vision and mission of the strategic 

framework? 

a. What is the most effective way to 

ensure the sustainability of initiatives 

that seek to enhance the integration of 

patient-centered outcomes research 

findings into practice? 

b. What complementary partnerships 

and collaborations (both public and 

private) would increase the impact of 

AHRQ’s PCORTF investments? 

c. What will be the best way of 

measuring progress and the overall 

impact of AHRQ’s PCORTF 

investments? 

6. Is there anything else you would 

like to share regarding the strategic 

framework? 

AHRQ is interested in all of the 

questions listed above, but respondents 

are welcome to address as many or as 

few as they choose and to address 

additional areas of interest not listed. It 

is helpful to identify which question a 

particular answer is a response to. 

This RFI is for planning purposes 

only and should not be construed as a 

policy, solicitation for applications, or 

as an obligation on the part of the 

Government to provide support for any 

ideas identified in response to it. AHRQ 

will use the information submitted in 

response to this RFI at its discretion and 

will not provide comments to any 

responder’s submission. However, 

responses to the RFI may be reflected in 

future solicitation(s) or policies. The 

information provided will be analyzed 

and may appear in reports. Respondents 

will not be identified in any published 

reports. Respondents are advised that 

the Government is under no obligation 

to acknowledge receipt of the 

information received or provide 

feedback to respondents with respect to 

any information submitted. No 

proprietary, classified, confidential, or 

sensitive information should be 

included in your response. The contents 

of all submissions will be made 

available to the public upon request. 

Materials submitted must be publicly 

available or able to be made public. 

Dated: April 11, 2022. 

Marquita Cullom, 

Associate Director. 

[FR Doc. 2022–08038 Filed 4–14–22; 8:45 am] 

BILLING CODE 4160–90–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended, and the Determination of 

the Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, CDC, pursuant to 

Public Law 92–463. The grant 

applications and the discussions could 

disclose confidential trade secrets or 

commercial property such as patentable 

material, and personal information 

concerning individuals associated with 

the grant applications, the disclosure of 

which would constitute a clearly 

unwarranted invasion of personal 

privacy. 

Name of Committee: Disease, 

Disability, and Injury Prevention and 

Control Special Emphasis Panel (SEP)— 

RFA–OH–20–002, Commercial Fishing 

Occupational Safety Research 

Cooperative Agreement; and RFA–OH– 

20–003, Commercial Fishing 

Occupational Safety Training Project 

Grants. 

Date: May 18, 2022. 

Time: 12:00 p.m.–3:00 p.m., EDT. 

Place: Video-Assisted Meeting. 

Agenda: To review and evaluate grant 

applications. 

FOR FURTHER INFORMATION CONTACT: 

Michael Goldcamp, Ph.D., Scientific 

Review Officer, Office of Extramural 

Programs, National Institute for 

Occupational Safety and Health, CDC, 

1095 Willowdale Road, Morgantown, 

West Virginia 26505, Telephone: (304) 

285–5951; Email: MGoldcamp@cdc.gov. 

The Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Strategic Business Initiatives Unit, 

Office of the Chief Operating Officer, Centers 

for Disease Control and Prevention. 

[FR Doc. 2022–08051 Filed 4–14–22; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Medicare & Medicaid 

Services 

[CMS–3423–N] 

Announcement of the Re-Approval of 

the American Society of 

Histocompatibility and 

Immunogenetics (ASHI) as an 

Accreditation Organization Under the 

Clinical Laboratory Improvement 

Amendments of 1988 

AGENCY: Centers for Medicare & 

Medicaid Services (CMS), HHS. 

ACTION: Notice. 

SUMMARY: This notice announces the 

application of the American Society for 

Histocompatibility and Immunogenetics 

(ASHI) for approval as an accreditation 

organization for clinical laboratories 

under the Clinical Laboratory 

Improvement Amendments of 1988 

(CLIA) program for the following 

specialty and subspecialty areas: 

General Immunology; 

Histocompatibility; and ABO/Rh typing. 

We have determined that the ASHI 

meets or exceeds the applicable CLIA 

requirements. In this notice, we 

announce the approval and grant the 

ASHI deeming authority for a period of 

6 years. 

DATES: This notice is effective from 

April 15, 2022 to April 15, 2028. 

FOR FURTHER INFORMATION CONTACT: 

Penny Keller, (410) 786–2035. 

SUPPLEMENTARY INFORMATION: 

I. Background and Legislative 

Authority 

On October 31, 1988, the Congress 

enacted the Clinical Laboratory 

Improvement Amendments of 1988 

(CLIA) (Pub. L. 100–578). CLIA 

amended section 353 of the Public 

Health Service Act. We issued a final 

rule implementing the accreditation 

provisions of CLIA on July 31, 1992 (57 

FR 33992). Under those provisions, 

CMS may grant deeming authority to an 

accreditation organization if its 

requirements for laboratories accredited 

under its program are equal to or more 

stringent than the applicable CLIA 

program requirements in 42 CFR part 

493 (Laboratory Requirements). Subpart 

E of part 493 (Accreditation by a Private, 

Nonprofit Accreditation Organization or 

Exemption Under an Approved State 

Laboratory Program) specifies the 

requirements an accreditation 

organization must meet to be approved 

by CMS as an accreditation organization 

under CLIA. 


jspears on DSK121TN23PROD with NOTICES1